How do you incorporate absolute percent pattern 4 (APP4) into your risk stratification, specifically your recommendation for ADT for intermediate prostate cancer?  

Given the importance of minimizing financial toxicity, for patients who have borderline unfavorable intermediate characteristics, is it reasonable to use APP4 in lieu of genomic/AI testing in low-resource patient settings to better select patients for ADT?